Prognosis of metastasis based on age and serum analytes after follow-up of non-metastatic lung cancer patients

Balla, Murali Mohan Sagar; Patwardhan, Sejal; Melwani, Pooja Kamal; Purwar, Pallavi; Kumar, Amit; Pramesh, C.S.; Laskar, Siddharth; Pandey, Badri N.

doi:10.1016/j.tranon.2020.100933

Cited by 3 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results show that serum levels of CEA, Cyfra21-1, IL-8 and VEGF in LC patients were significantly higher (p < 0.0001) than in HC groups. This finding is in agreement with previous studies [13,15,16,[23][24][25][26]. Further markers such as HE4, MIF and TNF-α are likely not useful as serum biomarkers for detection of LC within this study.…”

Section: Discussionsupporting

confidence: 91%

A Potential Serum Biomarker for Screening Lung Cancer Risk in High Level Environmental Radon Areas: A Pilot Study

Autsavapromporn

Klunklin

Chitapanarux

et al. 2021

Life

View full text Add to dashboard Cite

Radon is a major cause of lung cancer (LC) deaths among non-smokers worldwide. However, no serum biomarker for screening of LC risk in high residential radon (HRR) areas is available. Therefore, the aim of this study was to determine diagnostic values of serum carcinoembryonic antigen (CEA), cytokeratin 19 fragment (Cyfra21-1), human epididymis protein 4 (HE4), interleukin 8 (IL-8), migration inhibitory factor (MIF), tumor nuclear factor-alpha (TNF-α) and vascular endothelial growth factors (VEGF) occurring in high radon areas. Seventy-five LC non-smoker patients and seventy-five healthy controls (HC) were enrolled in this study. Among the HC groups, twenty-five HC were low residential radon (LRR) and fifty HC were HRR. Significantly higher (p < 0.0004) serum levels of CEA, Cyfra21-1, IL-8 and VEGF were found in the LC compared with the LRR and HRR groups. More importantly, significantly higher levels (p < 0.009) of serum CEA, Cyfra21-1 and IL-8 were observed in HRR compared with the LRR group. Likewise, a ROC curve demonstrated that serum CEA and Cyfra21-1 could better distinguish LC risk from HRR groups than IL-8. These results indicated that serum CEA and Cyfra21-1 were significantly increased in the HRR group and may be considered as potential biomarkers for individuals at high-risk to develop LC.

show abstract

Section: Discussionsupporting

confidence: 91%

A Potential Serum Biomarker for Screening Lung Cancer Risk in High Level Environmental Radon Areas: A Pilot Study

Autsavapromporn

Klunklin

Chitapanarux

et al. 2021

Life

View full text Add to dashboard Cite

show abstract

Systemic pharmacological verification of Salvia miltiorrhiza-Ginseng Chinese herb pair in inhibiting spontaneous breast cancer metastasis

Han¹,

Qian²,

Zong³

et al. 2022

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

A Nomogram for Predicting Cancer‐Specific Survival in Young Patients With Advanced Lung Cancer Based on Competing Risk Model

Li,

Pan,

Huang

et al. 2024

Clinical Respiratory J

View full text Add to dashboard Cite

BackgroundYoung lung cancer is a rare subgroup accounting for 5% of lung cancer. The aim of this study was to compare the causes of death (COD) among lung cancer patients of different age groups and construct a nomogram to predict cancer‐specific survival (CSS) in young patients with advanced stage.MethodsLung cancer patients diagnosed between 2004 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database and stratified into the young (18–45 years) and old (> 45 years) groups to compare their COD. Young patients diagnosed with advanced stage (IVa and IVb) from 2010 to 2015 were reselected and divided into training and validation cohorts (7:3). Independent prognostic factors were identified through the Fine‐Gray's test and further integrated to the competing risk model. The area under the receiver operating characteristic curve (AUC), consistency index (C‐index), and calibration curve were applied for validation.ResultsThe proportion of cancer‐specific death (CSD) in young patients was higher than that in old patients with early‐stage lung cancer (p < 0.001), while there was no difference in the advanced stage (p = 0.999). Through univariate and multivariate analysis, 10 variables were identified as independent prognostic factors for CSS. The AUC of the 1‐, 3‐, and 5‐year prediction of CSS was 0.688, 0.706, and 0.791 in the training cohort and 0.747, 0.752, and 0.719 in the validation cohort. The calibration curves demonstrated great accuracy. The C‐index of the competing risk model was 0.692 (95% CI: 0.636–0.747) in the young patient cohort.ConclusionYoung lung cancer is a distinct entity with a different spectrum of competing risk events. The construction of our nomogram can provide new insights into the management of young patients with lung cancer.

show abstract

Prognosis of metastasis based on age and serum analytes after follow-up of non-metastatic lung cancer patients

Abstract: Highlights Lower age of non-metastatic patients developed metastasis during follow-up. Higher levels of IL-8 and MMP-9 were observed in these patients. IL-8 and age together improved metastasis prognostic ability.

Cited by 3 publications

References 34 publications

A Potential Serum Biomarker for Screening Lung Cancer Risk in High Level Environmental Radon Areas: A Pilot Study

A Potential Serum Biomarker for Screening Lung Cancer Risk in High Level Environmental Radon Areas: A Pilot Study

Systemic pharmacological verification of Salvia miltiorrhiza-Ginseng Chinese herb pair in inhibiting spontaneous breast cancer metastasis

A Nomogram for Predicting Cancer‐Specific Survival in Young Patients With Advanced Lung Cancer Based on Competing Risk Model

Contact Info

Product

Resources

About